Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
IPH 4201 enters in pre-clinical validation
December 1, 2008
Innate Pharma SA announces the entry in pre-clinical validation of a new drug candidate: IPH 4201.
IPH 4201 is a monoclonal antibody targeting a specific antigen on pancreatic cancer cells.
| Download Area |
|---|
| PR in english |
| CP en français |